Antares Pharma Inc. has signed an agreement with an affiliate of Teva Pharmaceutical Industries Ltd. for Antares’ injection devices.

Under the terms of the agreement, the affiliate is obligated to purchase all of its delivery device requirements from Antares for an undisclosed product to be marketed in the United States only, claims a company release.

Jack E. Stover, president and CEO of Antares Pharma, said, “This agreement represents an important milestone for Antares’ injection devices, providing further validation of the benefits offered by our proprietary technology platforms. We are very pleased to have the opportunity to work with, and supply injection devices to Teva’s affiliate.”

Stover added, “We believe that our injectors offer compelling patient benefits versus conventional injection systems, which we think will differentiate our product from others currently available, and add value to a wide range of injectable generic and proprietary pharmaceutical products.”

Antares’ portfolio of injection devices includes the Vibex mini-needle injectors, and the Medi-Jector Vision and Medi-Jector Valeo needle-free injection systems. The Vibex mini-needle injectors utilise a very short 2.5 mm needle to reduce the pain sensation and avoid the unintended intra-muscular injections that can occur with conventional needle-based injection systems, such as auto-injectors and pen-injectors, and are protected by four issued United States patents and several additional patent applications. The company’s needle-free injectors are currently marketed for insulin delivery in the treatment of diabetes, and through pharmaceutical licensees for growth hormone delivery in the treatment of short stature in children.

Antares Pharma is a specialised pharma product development company with patented drug delivery systems and injectable device engineering capabilities.